Success Metrics

Completion Rate

0%(0/1)

Active Trials

1(33%)

Terminated

1(33%)

Phase Distribution

Ph phase_2

33%

Ph not_applicable

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(2)

Detailed Status

Active, not recruiting1

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

N/A1 (33.3%)

Trials by Status

active_not_recruiting133%

terminated133%

withdrawn133%

Recent Activity

1 active trials

Showing 3 of 3

terminatedphase_1

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

NCT04204941

active_not_recruitingnot_applicable

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

NCT01868451

withdrawnphase_2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

NCT03554109

Clinical Trials (3)

Showing 3 of 3 trials

NCT04204941Phase 1

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Terminated

NCT01868451Not Applicable

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active Not Recruiting

NCT03554109Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3